이 페이지의 번역은 실험적이며 개발 중입니다. 여러분의 환영합니다!

Jinling Pharmaceutical 관리

관리 기준 확인 1/4

현재 CEO에 대한 정보가 충분하지 않습니다.

주요 정보

Hai Chen

최고 경영자

n/a

총 보상

CEO 급여 비율	n/a
CEO 임기	1.1yrs
CEO 소유권	0.03%
경영진 평균 재임 기간	9.2yrs
이사회 평균 재임 기간	2.6yrs

최근 관리 업데이트

Recent updates

Earnings Troubles May Signal Larger Issues for Jinling Pharmaceutical (SZSE:000919) Shareholders

May 06

CEO

Hai Chen (44 yo)

1.1yrs

테뉴어

Mr. Hai Chen is Director, President and Board Secretary of Jinling Pharmaceutical Company Limited.

리더십 팀

이름	위치	테뉴어	보상	소유권
Yang Wang	VP, Chief Accountant & Non-Independent Director	no data	CN¥736.60k	0.039% CN¥ 1.6m
Sheng Chen	VP & Non-Independent Director	no data	CN¥739.80k	0.049% CN¥ 2.0m
Jian Wang	VP & Non-Independent Director	5.3yrs	CN¥741.70k	0.027% CN¥ 1.1m
Yajun Chen	President	3.6yrs	CN¥522.50k	0.033% CN¥ 1.4m
Jun Yang Xu	Secretary	25.8yrs	CN¥725.40k	0.026% CN¥ 1.1m
Xinning Zhu	Assistant to President	no data	CN¥485.40k	0.025% CN¥ 1.0m
Hai Chen	President	no data	데이터 없음	0.030% CN¥ 1.2m
Wei Guo Tang	Executive Vice President	13.1yrs	CN¥141.40k	데이터 없음
Zhenxin Xi	General Manager Assistant	no data	데이터 없음	0.016% CN¥ 649.1k

9.2yrs

평균 재임 기간

53.5yo

평균 연령

경험이 풍부한 관리: 000919 의 관리팀은 노련하고 경험 (평균 재직 기간 9.1 년)입니다.

이사회 구성원

이름	위치	테뉴어	보상	소유권
Yang Wang	VP, Chief Accountant & Non-Independent Director	1.1yrs	CN¥736.60k	0.039% CN¥ 1.6m
Sheng Chen	VP & Non-Independent Director	4.1yrs	CN¥739.80k	0.049% CN¥ 2.0m
Jian Wang	VP & Non-Independent Director	1.1yrs	CN¥741.70k	0.027% CN¥ 1.1m
Hai Chen	President	1.1yrs	데이터 없음	0.030% CN¥ 1.2m
Hongqin Li	Chairman of the Supervisory Board	7.1yrs	데이터 없음	데이터 없음
Yongjian Shen	Independent Director	4.1yrs	CN¥100.00k	데이터 없음
Yanping Gao	Independent Director	4.1yrs	CN¥100.00k	데이터 없음
Guangyu Yan	Non-Employee Supervisor	4.1yrs	데이터 없음	데이터 없음
Weijie Ye	Non-Employee Supervisor	4.1yrs	데이터 없음	데이터 없음
Xiaoqiang Cao	Non-independent Director	1.1yrs	데이터 없음	데이터 없음
Qunhong Zhang	Non-Independent Director	1.1yrs	데이터 없음	데이터 없음
Junping Kou	Independent Director	1.1yrs	데이터 없음	데이터 없음

2.6yrs

평균 재임 기간

46yo

평균 연령

경험이 풍부한 이사회: 000919 의 이사회는 경험(평균 재직 기간 2.5 년)으로 간주되지 않으므로 새 이사회가 필요합니다.

Jinling Pharmaceutical 관리

관리 기준 확인 1/4

주요 정보

최근 관리 업데이트

Jinling Pharmaceutical Company Limited, Annual General Meeting, May 21, 2024

High number of new directors

Jinling Pharmaceutical Company Limited Approves Management Appointments

Jinling Pharmaceutical Company Limited, Annual General Meeting, May 23, 2023

High number of new and inexperienced directors

High number of new directors

Recent updates

Jinling Pharmaceutical Company Limited to Report First Half, 2024 Results on Aug 27, 2024

Jinling Pharmaceutical Company Limited Announces Final Dividend on A Shares for the Year 2023, Payable on 31 May 2024

Earnings Troubles May Signal Larger Issues for Jinling Pharmaceutical (SZSE:000919) Shareholders

Jinling Pharmaceutical Company Limited, Annual General Meeting, May 21, 2024

First quarter 2024 earnings released: EPS: CN¥0.085 (vs CN¥0.087 in 1Q 2023)

New minor risk - Shareholder dilution

Jinling Pharmaceutical Company Limited to Report Q1, 2024 Results on Apr 30, 2024

Investor sentiment deteriorates as stock falls 15%

Jinling Pharmaceutical Company Limited to Report Fiscal Year 2023 Results on Mar 26, 2024

Third quarter 2023 earnings released: EPS: CN¥0.04 (vs CN¥0.066 in 3Q 2022)

Jinling Pharmaceutical Company Limited to Report Q3, 2023 Results on Oct 31, 2023

Second quarter 2023 earnings released: EPS: CN¥0.067 (vs CN¥0.039 in 2Q 2022)

High number of new directors

Jinling Pharmaceutical Company Limited Approves Management Appointments

Jinling Pharmaceutical Company Limited, Annual General Meeting, May 23, 2023

Full year 2022 earnings released: EPS: CN¥0.21 (vs CN¥0.24 in FY 2021)

Investor sentiment deteriorated over the past week

Investor sentiment improved over the past week

High number of new and inexperienced directors

Third quarter 2022 earnings released: EPS: CN¥0.066 (vs CN¥0.043 in 3Q 2021)

Second quarter 2022 earnings released: EPS: CN¥0.039 (vs CN¥0.081 in 2Q 2021)

Jinling Pharmaceutical Company Limited Implements Final Profit Distribution for 2021, Payable on August 11, 2022

High number of new directors

Jinling Pharmaceutical Company Limited Approves Cash Dividend for the Year 2021

Jinling Pharmaceutical Company Limited, Annual General Meeting, Jun 28, 2022

First quarter 2022 earnings: EPS and revenues miss analyst expectations

Jinling Pharmaceutical Company Limited Proposes Final Cash Dividend for the Year 2021

Full year 2021 earnings: EPS and revenues miss analyst expectations

Third quarter 2021 earnings released: EPS CN¥0.043 (vs CN¥0.11 in 3Q 2020)

Second quarter 2021 earnings released: EPS CN¥0.081 (vs CN¥0.10 in 2Q 2020)

Investor sentiment improved over the past week

First quarter 2021 earnings released: EPS CN¥0.069 (vs CN¥0.055 loss in 1Q 2020)

Investor sentiment improved over the past week

Full year 2020 earnings released: EPS CN¥0.13 (vs CN¥0.29 in FY 2019)

Jinling Pharmaceutical Company Limited to Report Fiscal Year 2020 Results on Mar 30, 2021

New 90-day low: CN¥6.50

New 90-day high: CN¥8.02

New 90-day high: CN¥7.50

Third quarter earnings released

New 90-day low: CN¥6.61

Earnings released

Jinling Pharmaceutical Company Limited to Report First Half, 2020 Results on Aug 25, 2020

New 90-day high - CN¥7.34

CEO

테뉴어

리더십 팀

평균 재임 기간

평균 연령

이사회 구성원

평균 재임 기간

평균 연령